BiotechTube

Apatinib and Adebrelimab in Combination With chemotherapy

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholangiocarcinoma (Icc)

Conditions

Intrahepatic Cholangiocarcinoma (Icc)

Trial Timeline

Jan 22, 2025 → Oct 1, 2027

NCT ID
NCT06925516

About Apatinib and Adebrelimab in Combination With chemotherapy

Apatinib and Adebrelimab in Combination With chemotherapy is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Intrahepatic Cholangiocarcinoma (Icc). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06925516. Target conditions include Intrahepatic Cholangiocarcinoma (Icc).

What happened to similar drugs?

0 of 4 similar drugs in Intrahepatic Cholangiocarcinoma (Icc) were approved

Approved (0) Terminated (1) Active (3)
🔄A4250 (odevixibat)IpsenPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
❌Maralixibat + PlaceboMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06925516Phase 2Recruiting

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma (Icc)

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
31
ApatinibJiangsu Hengrui MedicinePhase 2
35
FamitinibJiangsu Hengrui MedicinePhase 2
27
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
31
Durvalumab + SNDX-6352AstraZenecaPhase 2
35
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Pemigatinib + DurvalumabAstraZenecaPhase 2
42
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
42
PemigatinibIncytePhase 2
24
A4250 (odevixibat)IpsenPhase 3
37
OdevixibatIpsenPre-clinical
23
CGT4859Cogent BiosciencesPhase 1/2
36
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
32
MaralixibatMirum PharmaceuticalsPhase 3
37
MaralixibatMirum PharmaceuticalsPhase 2
39
MaralixibatMirum PharmaceuticalsPhase 2
32
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
24
MaralixibatMirum PharmaceuticalsPhase 3
37
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
29
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
23